01323nas a2200217   4500000000100000008004100001260001300042653002600055653001100081653001200092653001500104653002200119653001700141100001700158700001300175245004500188300000800233490000700241520084300248022001401091       2013                            d  c2013 Jul10aAnti-Bacterial Agents10aHumans10aleprosy10aQuinolones10aTreatment Outcome10aTuberculosis1 aRubinstein E1 aKeynan Y00aQuinolones for mycobacterial infections.  a1-40 v423 a<p>The fluoroquinolones (FQs) are important agents for the treatment of mycobacterial infections. In leprosy, the use of FQs has enabled a dramatic shortening of formerly long and complicated therapy. Both animal and human studies support the inclusion of certain FQs as a cornerstone of leprosy therapy. In tuberculosis (TB), particularly in multidrug-resistant (MDR) infections, the place of the major antimycobacterial FQs is less clear as there is widespread resistance to these agents in areas of the world in which MDR-TB and extensively drug-resistant (XDR)-TB are prevalent, particularly in Southeast Asia. The place of the newly developed FQ-related diarylquinoline compound known as bedaquiline in the treatment of drug-resistant TB is unclear; however, human studies suggest that it might be effective for this indication. </p>  a1872-7913